Merz Therapeutics has acquired assets from Acorda Therapeutics Inc. for $185 million, bringing two novel therapeutics for Parkinson’s disease and multiple sclerosis into its pipeline. The acquisition includes Inbrija, a levodopa inhalation powder for PD, and Fampyra, a prolonged release tablet for MS patients with walking difficulties. Inbrija is designed to address “off” symptoms of PD for those already taking carbidopa/levodopa. Fampyra is related to Ampyra, previously approved by the FDA. Merz Therapeutics CEO, Stefan König, highlighted the deal as a strategic move to strengthen the company’s position in the neurology space and expand into the MS segment.
Source link
In $185M deal, Merz purchases Parkinson’s, MS therapeutics from Acorda
